Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Andrew S. Koenig"'
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-17 (2018)
Abstract Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate
Externí odkaz:
https://doaj.org/article/e3446c2bebe345bfb750fced48f4d78b
Autor:
George W. Reed, David H. Collier, Andrew S. Koenig, Katherine C. Saunders, Dimitrios A. Pappas, Heather J. Litman, Joel M. Kremer, Sameer Kotak
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-8 (2017)
Abstract Background We examined models to predict disease activity transitions from moderate to low or severe and associated factors in patients with rheumatoid arthritis (RA). Methods Data from RA patients enrolled in the Corrona registry (October 2
Externí odkaz:
https://doaj.org/article/15ba95ac9b944dc89ed9cf857cda8def
Autor:
Betsy J Lahue, Rajiv Mallick, Xiang Zhang, Julien Heidt, Yufei Song, Andrew S Koenig, Gabriela Espinoza
Publikováno v:
Immunotherapy. 14:1245-1261
Secondary immunodeficiency (SID) occurs when the immune system is weakened by external factors, including certain medical treatments. It can leave a person with an increased risk of potentially serious or even fatal infections, as they no longer have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7db011043e5999834000d1937a462fa
https://doi.org/10.2217/imt-2022-0142
https://doi.org/10.2217/imt-2022-0142
Autor:
Andrew S Koenig, Eleni Tiniakou, Laura Gutierrez-Alamillo, Livia Casciola-Rosen, Liliana Florea, Lisa Christopher-Stine, Sherry G Leung, Grazyna Purwin, Jamie Perin, Julie J. Paik, Corina Antonescu, Jemima Albayda, Joseph Y. Shin, Doris G. Leung
Publikováno v:
Arthritis Rheumatol
Objective This open-label 12-week study was conducted to evaluate the efficacy and safety of tofacitinib, a JAK inhibitor, in treatment-refractory active dermatomyositis (DM). Methods Tofacitinib in extended-release doses of 11 mg was administered da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c891641510875c4d17dc0502b032d92d
https://doi.org/10.1002/art.41602
https://doi.org/10.1002/art.41602
Autor:
Laura Gutierrez-Alamillo, Matthew Shneyderman, Julie J. Paik, Lisa Christopher-Stine, Andrew S Koenig, Grazyna Purwin, Jemima Albayda, Livia Casciola-Rosen, Sherry Leung, Jamie Perin, Eleni Tiniakou, Doris G. Leung
Publikováno v:
Arthritis Rheumatol
We previously demonstrated that tofacitinib was effective in treating skin-predominant refractory dermatomyositis (DM) at 12 weeks in a prospective open label clinical trial, Study of Tofacitinib In Refractory dermatomyositis (STIR) (1). Here, we rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f61e5f0a7fce0a5b3474bf9033d60027
https://doi.org/10.1002/art.41944
https://doi.org/10.1002/art.41944
Autor:
Gwenael Guillard, Philip G. Conaghan, John Andrews, Mikkel Østergaard, Orrin Troum, Amy Stein, Z. Xie, Bethanie Wilkinson, Michael A. Bowes, Andrew S Koenig, Douglass Chapman
Publikováno v:
Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)
Conaghan, P G, Østergaard, M, Troum, O, Bowes, M A, Guillard, G, Wilkinson, B, Xie, Z, Andrews, J, Stein, A, Chapman, D & Koenig, A 2019, ' Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis ', Arthritis Research and Therapy, vol. 21, 214 . https://doi.org/10.1186/s13075-019-2000-1
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-6 (2019)
Conaghan, P G, Østergaard, M, Troum, O, Bowes, M A, Guillard, G, Wilkinson, B, Xie, Z, Andrews, J, Stein, A, Chapman, D & Koenig, A 2019, ' Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis ', Arthritis Research and Therapy, vol. 21, 214 . https://doi.org/10.1186/s13075-019-2000-1
Background The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA). Methods This was a post
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f82a504eaae92ddee19d5e95b0b9d07
Publikováno v:
Blood. 138:4071-4071
Secondary immunodeficiency (SID) is an acquired condition caused by several factors including, but not limited to, B-cell malignancies, and may result in frequent, burdensome, and possibly life-threatening infections. Treatment guidelines recommend i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0f13a69aef679762396b5a06784a8d1
https://doi.org/10.1182/blood-2021-145581
https://doi.org/10.1182/blood-2021-145581
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:1457-1471
Real-world data comparing tofacitinib with biologic disease-modifying antirheumatic drugs (bDMARDs) are limited.To compare characteristics, treatment patterns, and costs of patients with rheumatoid arthritis (RA) receiving tofacitinib versus the most
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d65c3c69f2282c86de9ef2eb988552f2
https://doi.org/10.18553/jmcp.2016.22.12.1457
https://doi.org/10.18553/jmcp.2016.22.12.1457
Publikováno v:
Clinical Therapeutics. 38:1451-1463
Tofacitinib is an oral Janus kinase inhibitor indicated for the treatment of rheumatoid arthritis (RA). Tofacitinib can be administered as a monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::922d605344f7bf4bd19fddcf1f48b33c
https://doi.org/10.1016/j.clinthera.2016.03.038
https://doi.org/10.1016/j.clinthera.2016.03.038
Autor:
Jeffrey A Bourret, James Harnett, Andrew S Koenig, Daniel Wiederkehr, Robert A. Gerber, David Gruben
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:209-218
Adherence to biologic disease-modifying antirheumatic drugs (bDMARDs) among patients with rheumatoid arthritis (RA) is often suboptimal in routine clinical practice. Low or nonadherence can reduce the effectiveness of bDMARD therapies.To evaluate fil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43a9b318c2ff6d1e32a77e8a749cf701
https://doi.org/10.18553/jmcp.2016.22.3.209
https://doi.org/10.18553/jmcp.2016.22.3.209